Search
R411
go.drugbank.com/drugs/DB05468ExperimentalIt is not immunosuppressive, but blocks the activation and recruitment of cells involved in respiratory inflammation.
Nitrofurantoin
go.drugbank.com/drugs/DB00698ApprovedInvestigationalVet approved[A179830] Nitrofurantoin was granted FDA approval on 6 February 1953.[L6895] … [A179824] This drug is more resistant to the development of bacterial resistance because it acts on many targets at once.
Synonyms: N-(5-Nitrofurfurylidene)-1-aminohydantoinNasoVAX
go.drugbank.com/drugs/DB15859InvestigationalAs of June 2020, NasoVAX is being evaluated in a Phase 2 clinical trial for safety and effectivness in preventing worsening symptoms in hospitalized COVID-19 patients (NCT04442230). … The compound has already shown to be tolerated with no adverse effects or fever in healthy individuals with a nearly 6-fold cellular immune response in comparison to an injectable vaccine[L16313].
Phentolamine
go.drugbank.com/drugs/DB00692ApprovedInvestigationalPhentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointe...
Synonyms: 2-(N-(m-hydroxyphenyl)-p-toluidinomethyl)imidazolineADX-10061
go.drugbank.com/drugs/DB05419ExperimentalADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.
Peginterferon alfacon-1
go.drugbank.com/drugs/DB05860ExperimentalPEGylation is a technology for the chemical attachment of polyethylene glycol (PEG) polymer chains to a broad range of drug substances such as peptides and proteins including antibody fragments; small molecules, and other drugs. [Inferge...
Recombinant Human Thrombopoietin
go.drugbank.com/drugs/DB16364Investigational[A225691, A225696] This drug is used in the treatment of thrombocytopenia.
Abarelix
go.drugbank.com/drugs/DB00106ApprovedWithdrawnPraecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.
Human growth hormone-releasing peptide 3
go.drugbank.com/drugs/DB19227InvestigationalHuman growth hormone-releasing peptide 3 is under investigation in clinical trial NCT00846872 (Effect of Continuous GHRP-3 Infusion at on GH-IGF-I System, Blood Pressure, Glucose, and Insulin Resistance
Forodesine
go.drugbank.com/drugs/DB06185InvestigationalForodesine is a highly potent, orally active, rationally designed PNP inhibitor that has shown activity in preclinical studies with malignant cells and clinical utility against T-cell acute lymphoblastic